RecruitingPhase 1NCT07123129
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
An Open-label, Multicenter Phase I Clinical Study of SHR-7782 Injection in the Treatment of Advanced Malignant Cancer
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment
200 participants
Start Date
Aug 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria6
- Participate in the study voluntarily, sign the informed consent form.
- Subjects were able to provide primary or metastatic cancer samples.
- At least one measurable lesion (RECIST version 1.1).
- ECOG 0~1.
- With adequate organ functions.
- Expected survival time ≥ 12 weeks.
Exclusion Criteria11
- With untreated brain metastasis or active central nervous system tumor metastases.
- Imaging shows that the tumor invades large blood vessels or has unclear boundaries with blood vessels.
- Patients with other malignant tumors in the past or at the same time.
- Patients with clinical symptoms, uncontrolled, or moderate or above pleural effusion, pericardial effusion, or peritoneal effusion.
- Patients with a history of interstitial pneumonia or interstitial lung disease or non-infectious pneumonia requiring steroid treatment.
- With poorly controlled or severe cardiovascular disease.
- Bleeding events of NCI-CTCAE v5.0 grade ≥ 2 occurred within 1 month before the first medication.
- Subjects who had a serious infection within 1 month before the first medication.
- History of immunodeficiency.
- Known allergy to any component of the SHR-7782 product.
- According to the researcher's judgment, there are other factors that may affect the research results or cause the research to be terminated midway.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSHR-7782 Injection
SHR-7782 injection.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07123129